BioCentury
ARTICLE | Company News

Dart Therapeutics, Galapagos deal

March 25, 2013 7:00 AM UTC

Dart said it is developing DT-200 (formerly GLPG0492), which it obtained from Galapagos, for Duchenne muscular dystrophy (DMD). Galapagos licensed the worldwide development and commercialization rights to the compound to patient foundations Charley's Fund (Great Barrington, Mass.) and the Nash Avery Foundation (Edina, Minn.), which co-founded Dart. The foundations then transferred the rights to Dart under undisclosed terms. ...